Moving forward in good KarMMa in myeloma.
作者信息
Bianchi Giada
机构信息
Brigham and Women's Hospital.
Dana-Farber Cancer Institute.
出版信息
Blood. 2024 Dec 5;144(23):2367-2369. doi: 10.1182/blood.2024026428.
Abstract
摘要
相似文献
1
Moving forward in good KarMMa in myeloma.
Blood. 2024 Dec 5;144(23):2367-2369. doi: 10.1182/blood.2024026428.
2
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Blood Cancer J. 2021 Jun 18;11(6):116. doi: 10.1038/s41408-021-00507-2.
3
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Br J Haematol. 2024 Apr;204(4):1293-1299. doi: 10.1111/bjh.19302. Epub 2024 Jan 23.
4
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin. 2023 Jan;39(1):81-89. doi: 10.1080/03007995.2022.2139052. Epub 2022 Nov 15.
5
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Lancet Haematol. 2024 Mar;11(3):e216-e227. doi: 10.1016/S2352-3026(24)00005-X.
6
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.
Curr Med Res Opin. 2024 Sep;40(9):1597-1603. doi: 10.1080/03007995.2024.2391112. Epub 2024 Aug 22.
7
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Future Oncol. 2024;20(18):1221-1235. doi: 10.2217/fon-2023-0954. Epub 2024 Apr 23.
8
Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma.
BMC Med Res Methodol. 2022 Oct 15;22(1):272. doi: 10.1186/s12874-022-01745-z.
9
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
Adv Ther. 2023 Oct;40(10):4626-4638. doi: 10.1007/s12325-023-02623-w. Epub 2023 Aug 19.
10
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin. 2021 Oct;37(10):1779-1788. doi: 10.1080/03007995.2021.1953456. Epub 2021 Jul 23.
本文引用的文献
1
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Blood. 2024 Dec 5;144(23):2389-2401. doi: 10.1182/blood.2024024582.
2
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.
Nat Rev Clin Oncol. 2024 Aug;21(8):590-609. doi: 10.1038/s41571-024-00913-y. Epub 2024 Jul 3.
3
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432204. doi: 10.1200/EDBK_432204.
4
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
Cancer Cell. 2023 Apr 10;41(4):711-725.e6. doi: 10.1016/j.ccell.2023.02.008. Epub 2023 Mar 9.
5
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.
6
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.
Blood Cancer Discov. 2022 Nov 2;3(6):490-501. doi: 10.1158/2643-3230.BCD-22-0018.
7
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
8
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
9
Promising therapies in multiple myeloma.
Blood. 2015 Jul 16;126(3):300-10. doi: 10.1182/blood-2015-03-575365. Epub 2015 Jun 1.
Zotero 插件